Actinium Pharmaceuticals ATNM shares are trading higher after the company announced it completed enrollment in the pivotal Phase 3 SIERRA trial of iomab-B.
Actinium Pharmaceuticals' stock has been rising Wednesday, up 19.18% to a price of $6.87. The stock's current volume for the day is 746.12 thousand, which is approximately 435.17% of its previous 30-day average volume of 171.45 thousand.
The stock's 50-day moving average was $6.59 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $13.18 and fallen to a low of $5.7.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.